An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL ( ...
An Open-Label Extension Study With REQUIP (Ropinirole) CR for Subjects From Studies 101468/165, 101468/168 and 101468/169 An Open-Label Extension Study With REQUIP (Ropinirole) CR for Subjects From Studies 101468/165, 1014 ...
Parkinson Disease;Parkinson's Disease
Drug: Ropinirole XL (formerly CR)
GlaxoSmithKline
NULL
Completed
30 Years
N/A
All
419
Phase 3
United States;Belgium;Czech Republic;France;Hungary;Italy;Poland;Spain;United Kingdom;Germany;Philippines United States;Belgium;Czech Republic;France;Hungary;Italy;Poland;Spain;United Kingdom;Germany;Philip ...
Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164 Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinir ...
101648/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients With Parkinson's Disease Who Completed the Previous Ropinirole CR Studies 167 or 164 101648/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR ...